Actively Recruiting

Phase Not Applicable
Age: 22Years +
All Genders
ID06793059

Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)

Led by Jacobs institute · Updated on 2026-03-10

10

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the Pipeline22 Flex Embolization Device with Shield Technology22 for treating adults aged 22 years and older who have large or giant wide-necked intracranial aneurysms in specific parts of the internal carotid artery. This device is also studied for smaller wide-necked aneurysms arising from parent vessels of certain sizes. The study aims to collect clinical evidence on the approved use of this device for endovascular treatment of these aneurysms. Participants will receive treatment with the Pipeline SHIELD Device, which is a flow diverter technology designed to manage intracranial aneurysms. The treatment involves endovascular placement of the device in the affected artery segments as specified. There is one study arm using this active treatment device. The study does not involve masking or blinding. During the study, participants will be monitored for the occurrence of thromboembolic events over a 12-month period. Researchers will evaluate safety outcomes related to these events. The overall study period spans from the start date in 2025 through an observation of outcomes up to 12 months after treatment. Participants will be adults able to provide consent or have a legally authorized representative available.

CONDITIONS

Brief Title

Evaluation of Flow Diverter Technology Device for Intracranial Aneurysm (SHIELD)

Who Can Participate

Age: 22Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults 22 years of age or older
  • Diagnosis of large or giant wide-necked intracranial aneurysms in the internal carotid artery from the petrous to the superior hypophyseal segments
  • Able to provide consent or have a legally authorized representative available to provide consent
Not Eligible

You will not qualify if you...

  • Unable to provide consent and no legally authorized representative available to provide consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Single procedure

Participants receive the Pipeline SHIELD device for the endovascular treatment of intracranial aneurysms.

1 procedure visit (in-person)

Post-operative Follow-up

Duration - Up to 12 months

Participants are monitored for safety and effectiveness after device implementation.

Multiple follow-up visits over 12 months

Trial Site Locations

Total: 1 location

1

Jacobs Institute

Buffalo, New York, United States, 14203

Actively Recruiting

Loading map...

Research Team

C

Carlos Pena, PhD, MS

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here